 Hodgkin Disease
"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Descriptor ID |
D006689
|
| MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
| Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1999 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 5 | 1 | 6 | | 2016 | 10 | 0 | 10 | | 2017 | 10 | 0 | 10 | | 2018 | 11 | 0 | 11 | | 2019 | 3 | 0 | 3 | | 2020 | 10 | 0 | 10 | | 2021 | 6 | 1 | 7 | | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 Jul 01; 107(7):1608-1618.
-
Lo AC, Major A, Super L, Appel B, Shankar A, Constine LS, Marks LJ, Kelly KM, Metzger ML, Buhtoiarov IN, Mauz-Körholz C, Costa ARS, Binkley MS, Flerlage J. Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW). Leuk Lymphoma. 2022 08; 63(8):1997-2000.
-
Kleinschmidt-DeMasters BK, Marshall CB, Cykowski MD. Paraneoplastic Lower Motor Neuron Disease. J Neuropathol Exp Neurol. 2021 12 29; 80(12):1125-1127.
-
Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A, Keller FG, Shukla N. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv. 2021 12 28; 5(24):5519-5524.
-
Milgrom SA, Bakst RL, Campbell BA. Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2021 11 15; 111(4):841-850.
-
Milgrom SA, Kim J, Chirindel A, Kim J, Pei Q, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Hoppe BS, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr Blood Cancer. 2021 09; 68(9):e29212.
-
Gillman AS, Vo JB, Nohria A, Ferrer RA. Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments. JNCI Cancer Spectr. 2021 08; 5(4).
-
Metzger ML, Link MP, Billett AL, Flerlage J, Lucas JT, Mandrell BN, Ehrhardt MJ, Bhakta N, Yock TI, Friedmann AM, de Alarcon P, Luna-Fineman S, Larsen E, Kaste SC, Shulkin B, Lu Z, Li C, Hiniker SM, Donaldson SS, Hudson MM, Krasin MJ. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. J Clin Oncol. 2021 07 10; 39(20):2276-2283.
-
Silva O, Charu V, Ewalt MD, Metcalf RA, Zhao S, Castellanos EM, Orellana E, Natkunam Y, Luna-Fineman S. Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment. Leuk Lymphoma. 2021 07; 62(7):1609-1618.
-
Milgrom SA, Dabaja BS, Mikhaeel NG. Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease? Leuk Lymphoma. 2021 07; 62(7):1554-1562.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|